Information  X 
Enter a valid email address

Valirx PLC Ord 0.1P (VAL)

Related News

29-May-2019 07:33 AM

ValiRx books annual loss as it develops cancer treatment candidates

Cancer therapy development group ValiRx booked a full-year loss as it continued to spend money developing and proving up its treatment candidates. Pre-tax losses for the year through December amounted to £4.8m, compared to losses of £3.6m on-
23-Oct-2018 02:35 PM

ValiRx to present at the Shares and AJ Bell investor evening event in Edinburgh on November 22, 2018

ValiRx (VAL) is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering. Register today and join Shares and AJ Bell Med
23-Jan-2018 11:14 AM

Valirx to present on 13 February 2018 at the Shares and AJ Bell Spotlight Evening in London

If you are looking for some new investment ideas for 2018, then come along the Shares and AJ Bell Investor Evening in London on Tuesday 13 February 2018. Directors from London Stock Exchange listed companies will present their latest plans regarding devel
11-Jan-2018 08:03 AM

ValiRx gets patent approval in the US

ValiRx, the clinical stage biotechnology company, has received patent approval in the US for its lead therapeutic compound, VAL201, which is in clinical trials. The patent application covers the molecule and use of compounds in pharmaceutically acceptabl
28-Sep-2017 08:33 AM

ValiRx cancer treatment JV progressing well

ValiRx, the clinical stage biotechnology company, said its joint venture with Tangent Reprofiling is progressing well. ValiSeek was formed to progress the novel cancer treatment drug, VAL401, into clinical efficacy trials for the treatment of lung cancer
26-Sep-2017 08:03 AM

ValiRx interim loss narrows

ValiRx has booked a narrower first-half loss after receiving R&D Tax Credits of around £650,000. Its loss before tax reduced slightly by 2.6% to £2.25m. The total comprehensive loss for the period was £1.99m, narrowing from £2.07
28-Jul-2017 09:04 AM

ValiRx signs first product licensing agreement

ValiRx (VAL), a clinical stage biotechnology company, has signed a licensing agreement with Mystic Pharmaceuticals in Bangladesh. Mystic gains immediate access to ValiRx's patented technology for its further development by Mystic for the benefit of
30-May-2017 03:01 PM

All resolutions passed at AGM of ValiRx

ValiRx has announced that, at its Annual General Meeting held earlier today, all resolutions were passed. At 3:01pm: (LON:VAL) ValiRx PLC share price was 0p at 2.4p Story provided by StockMarketWire.com...
08-May-2017 10:20 AM

Broker Forecast - Beaufort Securities issues a broker note on ValiRx PLC

Beaufort Securities today reaffirms its speculative buy investment rating on ValiRx PLC (LON:VAL) and set its price target at 6.50p. Story provided by StockMarketWire.com...
05-May-2017 07:46 AM

ValiRx widens FY pretax loss from continuing ops.

ValiRx has widened its FY pretax loss from continuing operations to £5.8m, which was more than double the prior year's loss of £2.24m. The wider loss was due to greater R&D costs and administrative expenses, along with a loss on derivati
01-Mar-2017 01:49 PM

ValiRx raises £1.16m via placing

ValiRx has raised £1.16m of gross proceeds through the issue of 46,509,015 new ordinary shares at a price of 2.5p per share. At 1:49pm: (LON:VAL) ValiRx PLC share price was -1.38p at 2.88p Story provided by StockMarketWire.com...
02-Dec-2016 04:29 PM

ValiRx loan draw down

ValiRx has drawn down the second tranche of its convertible loan facility with YA Global Master SPV Ltd for the amount of US$1,250,000. At 4:29pm: (LON:VAL) ValiRx PLC share price was -0.5p at 6.25p Story provided by StockMarketWire.com...
14-Jul-2016 07:47 AM

ValiRx issues ValiSeek clinical development update

ValiRx said ValiSeek has received a positive opinion recommending approval of the trial protocol for VAL401 from the Ethics Committee covering its clinical site in Tbilisi. It said this was a "significant step in the regulatory process prior to pati
07-Jul-2016 07:46 AM

ValiRx confirms sale of rights for TRAC Technology

ValiRx has confirmed the sale of use of rights for its Finnish-based TRAC Technology for €800,000. ValiRx has sold its subsidiary, ValiRx (Finland) Oy (ValiFinn), the company holding the TRAC technology, to Sovicell Science for Life GmbH, for a cash
26-Apr-2016 12:26 PM

ValiRx issues shares

ValiRx has announced that the Company has received a further conversion notice from Bracknor to convert GBP90k of its Convertible Loan Notes into ordinary shares in the Company. Following this conversion no Convertible Loan Notes remain outstanding. Con
04-Dec-2015 01:06 PM

Valirx Plc (VAL) to reveal plans for growth and development at the Shares Investor Evening on 15th D

Valirx Plc (VAL)[VAL] will be presenting its performance in the past year as well as its plans for growth and development at the free-to-attend Shares investor evening in London on 15th December 2015. About Valirx Plc (VAL) Valirx Plc (VAL) is an oncolo
27-May-2015 11:27 AM

ValiRx notes shares price increase

ValiRx has noted the recent increase in the Company's share price and confirmed that it is not aware of any reason that would lead to such a movement. At 11:27am: (LON:VAL) ValiRx PLC share price was +8p at 60p Story provided by StockMarketWir
15-May-2015 02:55 PM

ValiRx share consolidation approved

ValiRx has confirmed that all resolutions proposed at its annual general meeting today were passed - including a consolidation and sub-division of the company's share capital. Every 125 existing ordinary shares of 0.1p each will be consolidated int
07-May-2015 07:53 AM

ValiRx wins contract with Admescope Ltd

ValiRx said a contract has been secured with Admescope Ltd, for access to ValiRx's newly acquired 'TRAC' Finnish gene expression & biomarker technology. The assets and intellectual property rights of TRAC were originally acquired by ValiR
16-Apr-2015 07:45 AM

ValiRx widens FY pretax loss

ValiRx has widened its FY pretax loss to £3.6m, from £2.9m. Revenue was £87,558, from £124,868. Corporate highlights: · Lead drug VAL201 in Phase l/ll dose escalation clinical trials in patients with locally advanced or metastatic prostate can
13-Nov-2014 07:51 AM

ValiRx in collaboration agreement with DKFZ

ValiRx, the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, has entered into a collaboration agreement with the DKFZ for the further development of ValiRx's proprietary Gene Inactivation through Chr
02-Sep-2014 09:01 AM

ValiRx reports progress on novel cancer drug

ValiRx Plc (AIM: VAL), the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, has provided a further development and scientific update on the progress of pre-clinical studies at ValiSeek, its joint venture
27-May-2014 11:43 AM

Valirx to present at Shares Investor Evening on 10th June 2014

Valirx plc (VAL) (VAL.L) [LON: VAL] a biopharmaceutical company, will be presenting at the Shares Magazine evening in London on 10th June 2014. The event offers the opportunity to listen to directors present their latest plans regarding development and gr
08-Apr-2014 07:42 AM

ValiRx in risk-sharing JV with Tangent Reprofiling Ltd

ValiRx Plc, the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, has established ValiSeek Limited, a risk-sharing JV company with Tangent Reprofiling Limited. ValiSeek has acquired a worldwide exclusi
19-Mar-2014 07:42 AM

ValiRx widens FY pretax loss to £2.9m

ValiRx widened its FY pretax loss to £2.9m, from £2.3m. Revenue was £0.12m, from £0.22m. Research, development and administrative expenses accounted for most of the loss. "We now have a secure funding platform upon which we can consolidate the f
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t